$437 Million is the total value of Fairmount Funds Management LLC's 27 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 14.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| GBT | Sell | GLOBAL BLOOD THERAPEUTICS IN | $30,461,000 | -25.6% | 953,396 | -19.4% | 6.97% | -28.0% |
| ARGX | Sell | ARGENX SEsponsored adr | $27,858,000 | -28.9% | 73,526 | -40.8% | 6.38% | -31.2% |
| INSM | Sell | INSMED INC | $26,156,000 | -42.9% | 1,326,368 | -31.9% | 5.99% | -44.7% |
| PNT | Sell | POINT BIOPHARMA GLOBAL INC | $12,489,000 | -32.2% | 1,833,950 | -20.7% | 2.86% | -34.4% |
| ACAD | Sell | ACADIA PHARMACEUTICALS INC | $10,593,000 | -62.2% | 751,804 | -35.0% | 2.42% | -63.4% |
| KROS | Sell | KEROS THERAPEUTICS INC | $7,529,000 | -65.1% | 272,498 | -31.3% | 1.72% | -66.2% |
| PTGX | Exit | PROTAGONIST THERAPEUTICS INC | $0 | – | -549,988 | -100.0% | -3.08% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ARGENX SE | 16 | Q3 2023 | 9.3% |
| AXSOME THERAPEUTICS INC | 15 | Q3 2023 | 24.6% |
| INSMED INC | 12 | Q3 2022 | 15.0% |
| ACADIA PHARMACEUTICALS INC | 12 | Q3 2022 | 15.5% |
| IOVANCE BIOTHERAPEUTICS INC | 12 | Q3 2022 | 9.4% |
| COGENT BIOSCIENCES INC | 12 | Q3 2023 | 7.2% |
| ENANTA PHARMACEUTICALS INC | 12 | Q3 2022 | 9.6% |
| ALLAKOS INC | 12 | Q3 2022 | 7.4% |
| AMARIN CORP PLC | 12 | Q3 2022 | 10.9% |
| VERONA PHARMA PLC | 12 | Q2 2023 | 11.9% |
View Fairmount Funds Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | June 30, 2023 | 17,230,540 | 20.0% |
| Olema Pharmaceuticals, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| CATABASIS PHARMACEUTICALS INC | June 17, 2021 | 4,092,166 | 5.3% |
| MIRAGEN THERAPEUTICS, INC. | January 05, 2021 | 967,671 | 20.0% |
| Unum Therapeutics Inc. | July 10, 2020 | 7,482,460 | 20.0% |
View Fairmount Funds Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-05-16 |
| 13F-HR | 2024-05-15 |
| 4 | 2024-04-25 |
| SC 13D/A | 2024-04-25 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| SC 13D/A | 2024-04-01 |
| SC 13D/A | 2024-04-01 |
View Fairmount Funds Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.